| 9.81 0.39 (4.14%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.76 | 1-year : | 12.53 |
| Resists | First : | 10.07 | Second : | 10.73 |
| Pivot price | 9.65 |
|||
| Supports | First : | 9 | Second : | 7.48 |
| MAs | MA(5) : | 9.58 |
MA(20) : | 9.73 |
| MA(100) : | 11.9  |
MA(250) : | 15.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 47.2 |
D(3) : | 34.2 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 24.14 | Low : | 7.96 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALVR ] has closed below upper band by 33.6%. Bollinger Bands are 76.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.33 - 10.37 | 10.37 - 10.41 |
| Low: | 9.45 - 9.5 | 9.5 - 9.54 |
| Close: | 9.74 - 9.81 | 9.81 - 9.88 |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Fri, 21 Mar 2025
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Fri, 24 Jan 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - The Malaysian Reserve
Wed, 15 Jan 2025
AlloVir executes reverse stock split - Investing.com
Wed, 13 Nov 2024
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Fri, 08 Nov 2024
AlloVir and Kalaris Therapeutics Announce Agreement for - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 13.6 (%) |
| Shares Short | 59 (K) |
| Shares Short P.Month | 60 (K) |
| EPS | -11.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.4 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -68 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.84 |
| PEG Ratio | 0 |
| Price to Book value | 0.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|